321 related articles for article (PubMed ID: 26075833)
41. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions.
Snyder BD; Rowland A; Polasek TM; Miners JO; Doogue MP
Eur J Clin Pharmacol; 2014 Sep; 70(9):1115-22. PubMed ID: 25028073
[TBL] [Abstract][Full Text] [Related]
43. Simultaneous analysis of cytochrome P450 probes-dextromethorphan, flurbiprofen and midazolam and their major metabolites by HPLC-mass-spectrometry/fluorescence after single-step extraction from plasma.
Kumar A; Mann HJ; Remmel RP
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 853(1-2):287-93. PubMed ID: 17452028
[TBL] [Abstract][Full Text] [Related]
44. Monkey liver cytochrome P450 2C19 is involved in R- and S-warfarin 7-hydroxylation.
Hosoi Y; Uno Y; Murayama N; Fujino H; Shukuya M; Iwasaki K; Shimizu M; Utoh M; Yamazaki H
Biochem Pharmacol; 2012 Dec; 84(12):1691-5. PubMed ID: 23041648
[TBL] [Abstract][Full Text] [Related]
45. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs.
Nishimuta H; Houston JB; Galetin A
Drug Metab Dispos; 2014 Sep; 42(9):1522-31. PubMed ID: 24994071
[TBL] [Abstract][Full Text] [Related]
46. Prediction of oral pharmacokinetics of cMet kinase inhibitors in humans: physiologically based pharmacokinetic model versus traditional one-compartment model.
Yamazaki S; Skaptason J; Romero D; Vekich S; Jones HM; Tan W; Wilner KD; Koudriakova T
Drug Metab Dispos; 2011 Mar; 39(3):383-93. PubMed ID: 21098644
[TBL] [Abstract][Full Text] [Related]
47. In vitro and in vivo evaluation of the effect of puerarin on hepatic cytochrome p450-mediated drug metabolism.
Kim SB; Yoon IS; Kim KS; Cho SJ; Kim YS; Cho HJ; Chung SJ; Chong S; Kim DD
Planta Med; 2014 May; 80(7):561-7. PubMed ID: 24710899
[TBL] [Abstract][Full Text] [Related]
48. Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.
Barter ZE; Tucker GT; Rowland-Yeo K
Clin Pharmacokinet; 2013 Dec; 52(12):1085-100. PubMed ID: 23818090
[TBL] [Abstract][Full Text] [Related]
49. The species differences of intestinal drug absorption and first-pass metabolism between cynomolgus monkeys and humans.
Takahashi M; Washio T; Suzuki N; Igeta K; Yamashita S
J Pharm Sci; 2009 Nov; 98(11):4343-53. PubMed ID: 19230019
[TBL] [Abstract][Full Text] [Related]
50. Human plasma and urinary metabolic profiles of trimethylamine and trimethylamine N-oxide extrapolated using a simple physiologically based pharmacokinetic model.
Shimizu M; Yamazaki H
J Toxicol Sci; 2017; 42(4):485-490. PubMed ID: 28717107
[TBL] [Abstract][Full Text] [Related]
51. Stereoselectivity in pharmacokinetics of rivoglitazone, a novel peroxisome proliferator-activated receptor γ agonist, in rats and monkeys: model-based pharmacokinetic analysis and in vitro-in vivo extrapolation approach.
Izumi T; Tsuruta F; Ishizuka T; Nakamura K; Kothuma M; Takahashi M
J Pharm Sci; 2013 Sep; 102(9):3174-88. PubMed ID: 23686684
[TBL] [Abstract][Full Text] [Related]
52. Comparison of p450 enzymes between cynomolgus monkeys and humans: p450 identities, protein contents, kinetic parameters, and potential for inhibitory profiles.
Emoto C; Yoda N; Uno Y; Iwasaki K; Umehara K; Kashiyama E; Yamazaki H
Curr Drug Metab; 2013 Feb; 14(2):239-52. PubMed ID: 22963393
[TBL] [Abstract][Full Text] [Related]
53. Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.
Sharer JE; Shipley LA; Vandenbranden MR; Binkley SN; Wrighton SA
Drug Metab Dispos; 1995 Nov; 23(11):1231-41. PubMed ID: 8591724
[TBL] [Abstract][Full Text] [Related]
54. No regional differences of cytochrome P450 expression in the liver of Cynomolgus monkeys (Macaca fascicularis).
Akahori M; Takatori A; Kawamura S; Itagaki S; Yoshikawa Y
Exp Anim; 2005 Apr; 54(2):131-6. PubMed ID: 15897621
[TBL] [Abstract][Full Text] [Related]
55. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
56. Prediction of human pharmacokinetics from preclinical information of rhein, an antidiabetic nephropathy drug, using a physiologically based pharmacokinetic model.
Hao K; Qi Q; Wan P; Zhang J; Hao H; Liang Y; Xie L; Wang G; Sun J
Basic Clin Pharmacol Toxicol; 2014 Feb; 114(2):160-7. PubMed ID: 24118734
[TBL] [Abstract][Full Text] [Related]
57. Strong Induction of Cytochrome P450 1A/3A, But not P450 2B, in Cultured Hepatocytes from Common Marmosets and Cynomolgus Monkeys by Typical Human P450 Inducing Agents.
Uehara S; Uno Y; Suzuki T; Inoue T; Utoh M; Sasaki E; Yamazaki H
Drug Metab Lett; 2017; 10(4):244-253. PubMed ID: 27842484
[TBL] [Abstract][Full Text] [Related]
58. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
59. A Physiologically Based Pharmacokinetic Model to Predict the Impact of Metabolic Changes Associated with Metabolic Associated Fatty Liver Disease on Drug Exposure.
Newman EM; Rowland A
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233052
[TBL] [Abstract][Full Text] [Related]
60. Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan.
Uno Y; Uehara S; Kohara S; Murayama N; Yamazaki H
Drug Metab Dispos; 2010 Sep; 38(9):1486-92. PubMed ID: 20501912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
